NC-based Glaxo execs lobbying for more flights to Europe; No MMR vax-autism link, another study shows;

@FiercePharma: ICYMI: Gunning for a spot in the next-gen autoimmune market, Lilly med hits goals in latest trial. More | Follow @FiercePharma

@EricPFierce: Daiichi Sankyo appears to have had enough of Indian generics industry. Selling its $3B+ stake in Sun. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: $GSK yanks all doses of quadrivalent flu jab for potency problems. Report | Follow @CarlyHFierce

> North Carolina-based GlaxoSmithKline ($GSK) execs say there's still a need for a direct flight from Raleigh-Durham International to London--and they're speaking out in favor of flights to Paris, Frankfurt and beyond, too. More

> Fake and substandard drugs are responsible for tens of thousands of deaths around the world each year, researchers say. More

> A large study published by JAMA shows no link between the MMR vaccine and autism. More (sub. req.)

Medical Device News

@FierceMedDev: UPDATED: NEA-backed Cartiva raises $6M after a recent FDA nod, as it heads into a PMA review. Report | Follow @FierceMedDev

@VarunSaxena2: Study: Schizophrenics on J&J's injectable fare better than those on oral meds. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: LabCorp rides direct-to-consumer wave with online testing services. FierceDiagnostics story | Follow @EmilyWFierce

> Spirox reels in $18.5M for nasal obstruction device. Article

> Tal Medical gets $14M to sort out dosage, durability for fast-acting depression device. News

Biotech News

@FierceBiotech: Shifting positions, Genervon now says it has yet to file for ALS drug OK. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Gene therapy player Dimension stirs IPO buzz with $65M venture round
(we talked with CEO Annalisa Jenkins). Article | Follow @JohnCFierce

@DamianFierce: $TEVA bids $82 per share on $MYL. Release | Follow @DamianFierce

> Alnylam's star RNAi drug keeps the pace on the way to Phase III. Report

> Following a setback, Pfizer gets a win in Phase III cancer drug study. Story

> Surging Actelion is on the hunt for buyouts amid 'M&A frenzy.' Article

Drug Delivery News

> Icon heralds late-stage success for extended-release, postsurgical cataract treatment. Report

> Nanoparticle coating spurs oral cancer vaccine potential. Story

> Mersana's cancer-fighting antibody-drug conjugate shows promise in animal studies. Article

> 'Doc fix' reform bill alters Medicare reimbursement for some oral-only meds. Item

> Study: Schizophrenics on J&J's injectable fare better than those on oral meds. More

Pharma Manufacturing News

> Pfizer accused of misleading consumers with oversized Advil bottles. Item

> Novasep's 'focus' pays off for contract manufacturer. More

> GSK recalls vaccine made at troubled plant in Canada. News

> Merck injects another $12.4M in its newest vaccine plant. Story

> Daiichi Sankyo sold Ranbaxy's problems to Sun, now cashing in its stake. Article

Pharma Asia News

> India's Glenmark pulls in Singapore's Temasek money via preference shares. News

> China steps up decentralized drug industry regulation, market prices push. Story

> Indian drug firms eye 'paper tiger' status at home, clinical opportunities abroad. More

> Teva, Barr in largest ever pay-for-delay settlement. Article

> South Korea's Kosdaq bubbles along taking small pharma/biotech for a ride. Report

And Finally... Mindfulness therapy is as good as medication for chronic depression, a new study shows. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.